Abraxis mulls sale of company

Abraxis Bioscience has retained Goldman Sachs and Lazard to explore the possible sale of the company, sources tell dealReporter. The rumored deal talks follow the release of data last month showing the company's drug Abraxane demonstrated a significant improvement in overall response rate as compared with Taxol in a study of patients with advanced non-small cell lung cancer. Earlier this year, CEO Patrick Soon-Shiong said in an interview with the Financial Times that the company...